Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells

Beggiolin G, Crippa L, Menta E, Manzotti C, Cavalletti E, Pezzoni G, Torriani D, Randisi E, Cavagnoli R, Sala F, Giuliani FC, Spinelli S. (2001). Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori87: 407–416.10.1177/030089160108700611Search in Google Scholar

Borchmann P, Morschhauser F, Parry A, Schnell R, Harousseau JL, Gisselbrecht C, Rudolph C, Wilhelm M, Gunther H, Pfreundschuh DM, Camboni G, Engert A. (2003). Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin’s lymphomas. Haematologica88: 888–894.Search in Google Scholar

Capranico G, Tinelli S, Austin CA, Fisher ML, Zunino F. (1992). Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta1132: 43–48.10.1016/0167-4781(92)90050-ASearch in Google Scholar

Cavalletti E, Crippa L, Mainardi P, Oggioni N, Cavagnoli R, Bellini O, Sala F. (2007). Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs25: 187–195.10.1007/s10637-007-9037-8Search in Google Scholar

Conner CS. (1984). Mitoxantrone: a replacement for doxorubicin? Drug Intell Clin Pharm18: 479–480.10.1177/106002808401800604Search in Google Scholar

Corbett TH, Griswold DP Jr., Roberts BJ, Schabel FM Jr. (1981). Absence of delayed lethality in mice treated with aclacinomycin A. Cancer Chemother Pharmacol6: 161–168.10.1007/BF00262337Search in Google Scholar

Costa VM, Carvalho F, Bastos ML, Carvalho RA, Carvalho M, Remião F. (2011). Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases. Curr Med Chem18: 2272–2314.10.2174/092986711795656081Search in Google Scholar

Costa VM, Carvalho F, Duarte JA, Bastos ML, Remiao F. (2013). The heart as a target for xenobiotic toxicity: the cardiac susceptibility to oxidative stress. Chem Res Toxicol26: 1285–1311.10.1021/tx400130vSearch in Google Scholar

Costa VM, Silva R, Tavares LC, Vitorino R, Amado F, Carvalho F, Bastos ML, Carvalho M, Carvalho RA, Remiao F. (2009). Adrenaline and reactive oxygen species elicit proteome and energetic metabolism modifications in freshly isolated rat cardiomyocytes. Toxicology260: 84–96.10.1016/j.tox.2009.03.012Search in Google Scholar

Dawson LK, Jodrell DI, Bowman A, Rye R, Byrne B, Bernareggi A, Camboni G, Smyth JF. (2000). A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur J Cancer36: 2353–2359.10.1016/S0959-8049(00)00342-7Search in Google Scholar

El-Helw LM, Hancock BW. (2007). Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin’s lymphomas. Expert Opin Investig Drugs16: 1683–1691.10.1517/13543784.16.10.168317922631Search in Google Scholar

EMA. (2017). Pixuvri (pixantrone): EU summary of product characteristics. European Medicines Agency, London, UK.Search in Google Scholar

Faivre S, Raymond E, Boige V, Gatineau M, Buthaut X, Rixe O, Bernareggi A, Camboni G, Armand JP. (2001). A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin Cancer Res7: 43–50.Search in Google Scholar

FDA. (2010). FDA ODAC Briefing Document: Pixuvri (pixantrone). In: U.S.D.o.H.a.H. Services (Ed), Maryland, USA.Search in Google Scholar

Hasinoff BB, Wu X, Patel D, Kanagasabai R, Karmahapatra S, Yalowich JC. (2016). Mechanisms of action and reduced cardiotoxicity of pixantrone; a topoisomerase II targeting agent with cellular selectivity for the topoisom-erase II alpha isoform. J Pharmacol Exp Ther356: 397–409.10.1124/jpet.115.228650474649326660439Search in Google Scholar

Herman EH, Zhang J, Hasinoff BB, Clark JR Jr., Ferrans VJ. (1997). Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J Mol Cell Cardiol29: 2415–2430.10.1006/jmcc.1997.04779299365Search in Google Scholar

Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, Schultz G. (1991). Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ Res69: 1476–1486.10.1161/01.RES.69.6.1476Search in Google Scholar

Hrynchak I, Sousa E, Pinto M, Costa VM. (2017). The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs. Drug Metab Rev49: 158–196.10.1080/03602532.2017.131628528393622Search in Google Scholar

Kimes BW, Brandt BL. (1976). Properties of a clonal muscle cell line from rat heart. Exp Cell Res98: 367–381.10.1016/0014-4827(76)90447-XSearch in Google Scholar

Kluza J, Marchetti P, Gallego MA, Lancel S, Fournier C, Loyens A, Beauvillain JC, Bailly C. (2004). Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene23: 7018–7030.10.1038/sj.onc.1207936Search in Google Scholar

Krapcho AP, Petry ME, Getahun Z, Landi JJJr, Stallman J, Polsenberg JF, Gallagher CE, Maresch MJ, Hacker MP, Giuliani FC, Beggiolin G, Pezzoni G, Menta E, Manzotti C, Oliva A, Spinelli S, Tognella S. (1994). 6,9-Bis[(aminoalkyl) amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations. J Med Chem37: 828–837.10.1021/jm00032a018Search in Google Scholar

Lopes MA, Meisel A, Dirnagl U, Carvalho FD, Bastos ML. (2008). Doxorubicin induces biphasic neurotoxicity to rat cortical neurons. Neurotoxicology29: 286–293.10.1016/j.neuro.2007.12.003Search in Google Scholar

Malisza KL, Hasinoff BB. (1995). Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system. Arch Biochem Biophys321: 51–60.10.1006/abbi.1995.1367Search in Google Scholar

Menard C, Pupier S, Mornet D, Kitzmann M, Nargeot J, Lory P. (1999). Modulation of L-type calcium channel expression during retinoic acid-induced differentiation of H9c2 cardiac cells. J Biol Chem274: 29063–29070.10.1074/jbc.274.41.29063Search in Google Scholar

Péan E, Flores B, Hudson I, Sjöberg J, Dunder K, Salmonson T, Gisselbrecht C, Laane E, Pignatti F. (2013). The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-hodgkin’s b-cell lymphomas: Summary of the scientific assessment of the committee for medicinal products for human use. Oncologist18: 625–633.10.1634/theoncologist.2013-0020Search in Google Scholar

Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. (2012). Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol13: 696–706.10.1016/S1470-2045(12)70212-7Search in Google Scholar

Reis-Mendes A, Gomes AS, Carvalho RA, Carvalho F, Remiao F, Pinto M, Bastos ML, Sousa E, Costa VM. (2017). Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy. Arch Toxicol91: 1871–1890.10.1007/s00204-016-1839-zSearch in Google Scholar

Reis-Mendes AF, Sousa E, de Lourdes Bastos M, Costa VM. (2015). The role of the metabolism of anticancer drugs in their induced-cardiotoxicity. Curr Drug Metab17: 75–90.10.2174/1389200216666151103114926Search in Google Scholar

Repetto G, del Peso A, Zurita JL. (2008). Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc3: 1125–1131.10.1038/nprot.2008.75Search in Google Scholar

Rossato LG, Costa VM, Dallegrave E, Arbo M, Silva R, Ferreira R, Amado F, Dinis-Oliveira RJ, Duarte JA, de Lourdes Bastos M, Palmeira C, Remiao F. (2014). Mitochondrial cumulative damage induced by mitoxantrone: late onset cardiac energetic impairment. Cardiovasc Toxicol14: 30–40.10.1007/s12012-013-9230-2Search in Google Scholar

Rossato LG, Costa VM, Vilas-Boas V, de Lourdes Bastos M, Rolo A, Palmeira C, Remiao F. (2013). Therapeutic concentrations of mitoxantrone elicit energetic imbalance in H9c2 cells as an earlier event. Cardiovasc Toxicol13: 413–425.10.1007/s12012-013-9224-0Search in Google Scholar

Ruiz M, Courilleau D, Jullian JC, Fortin D, Ventura-Clapier R, Blondeau JP, Garnier A. (2012). A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1alpha expression and mitochondrial biogenesis. PLoS One7: e46753.10.1371/journal.pone.0046753Search in Google Scholar

Salvatorelli E, Menna P, Paz OG, Chello M, Covino E, Singer JW, Minotti G. (2013). The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther344: 467–478.10.1124/jpet.112.200568Search in Google Scholar

Sardão VA, Oliveira PJ, Holy J, Oliveira CR, Wallace KB. (2009). Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemother Pharmacol64: 811–827.10.1007/s00280-009-0932-xSearch in Google Scholar

Soares AS, Costa VM, Diniz C, Fresco P. (2013). Potentiation of cytotoxicity of paclitaxel in combination with Cl-IB-MECA in human C32 metastatic melanoma cells: A new possible therapeutic strategy for melanoma. Biomed Pharmacother67: 777–789.10.1016/j.biopha.2013.08.003Search in Google Scholar

Stuart-Harris RC, Bozek T, Pavlidis NA, Smith IE. (1984). Mitoxantrone: an active new agent in the treatment of advanced breast cancer. Cancer Che-mother Pharmacol12: 1–4.10.1007/BF00255899Search in Google Scholar

Volpetti S, Zaja F, Fanin R. (2014). Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Onco Targets Ther7: 865–872.10.2147/OTT.S34055Search in Google Scholar

Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET. (2012). Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med18: 1639–1642.10.1038/nm.2919Search in Google Scholar

Zhang YY, Meng C, Zhang XM, Yuan CH, Wen MD, Chen Z, Dong DC, Gao YH, Liu C, Zhang Z. (2015). Ophiopogonin D attenuates doxorubicin-induced autophagic cell death by relieving mitochondrial damage in vitro and in vivo. J Pharmacol Exp Ther352: 166–174.10.1124/jpet.114.219261Search in Google Scholar

Zordoky BN, El-Kadi AO. (2007). H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. J Pharmacol Toxicol Methods56: 317–322.10.1016/j.vascn.2007.06.001Search in Google Scholar